Ergoteles’s Prelude Therapeutics PRLD Stock Holding History

Ergoteles’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-43,500	Closed	-$227K	–	1887
2022 Q2	$227K	Buy	+43,500	New	+$221K	0.01%	1257

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ergoteles's PRLD Position: Q3 2022 in Review

Ergoteles sold out of Prelude Therapeutics (PRLD) in Q3 2022, closing a stake of 43,500 shares — an estimated $227K sold.

Ergoteles first reported a position in PRLD in Q2 2022 and held it in 1 quarter. The position peaked at $227K in Q2 2022. 53 funds tracked by Wall St. Rank hold PRLD as of Q3 2022.

Ergoteles reported no remaining Prelude Therapeutics position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 43,500 Prelude Therapeutics shares in Q3 2022, an estimated $227K.
Ergoteles first reported a position in Prelude Therapeutics in Q2 2022 and held it in 1 quarter.
Ergoteles's Prelude Therapeutics position peaked at $227K in Q2 2022.
53 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.